Trial Profile
Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ulixertinib (Primary)
- Indications Colorectal cancer; Gallbladder cancer; Gastrointestinal cancer; Glioblastoma; Head and neck cancer; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Salivary gland cancer; Solid tumours; Squamous cell cancer; Thyroid cancer
- Focus Adverse reactions; First in man
- Sponsors BioMed Valley Discoveries
- 03 Jan 2021 Results assessing dAEs in patients treated with ulixertinib and analyze the correlation between dAEs and tumor responses, published in the Investigational New Drugs.
- 19 Sep 2018 Status changed from active, no longer recruiting to completed.
- 17 Jan 2018 Planned End Date changed from 1 Jul 2017 to 1 Feb 2019.